Based on the Si-Bone Inc stock forecast from 4 analysts, the average analyst target price for Si-Bone Inc is USD 19.75 over the next 12 months. Si-Bone Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Si-Bone Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Si-Bone Inc’s stock price was USD 13.60. Si-Bone Inc’s stock price has changed by -2.79% over the past week, -22.60% over the past month and -14.20% over the last year.
No recent analyst target price found for Si-Bone Inc
No recent average analyst rating found for Si-Bone Inc
Company Overview Si-Bone Inc
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degeneration, adult deformity and degeneration, and pelvic trauma, as well as implantable bone products. It also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with a proprietary 3D-printed porous surface and fenestrated design; iFuse TORQ, a line of 3D-printed threaded implants designed for applications in pelvic trauma and sacroliliac fusion; and iFuse Bedrock Granite Implant System that provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion; and iFuse TORQ TNT to treat pelvic trauma and sacroiliac joint dysfunction, as well as iFuse INTRA implants that are marketed as human cells, tissues, and cellular or tissue-based products. The company markets its products primarily with a direct sales force, as well as through third-party sales agent and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. Read Less
SI-BONE, Inc., a medical device company, focuses on solving musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. The company offers proprietary minimally invasive surgical implant systems to address sacroiliac joint dysfunction and degene...Read More
Frequently Asked Questions About Si-Bone Inc (SIBN) Stock
Based on ratings from 4 analysts Si-Bone Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on SIBN's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for SIBN is USD 19.75 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 15.
Unfortunately we do not have enough data on SIBN's stock to indicate if its overvalued.
The last closing price of SIBN's stock was USD 13.60.
The most recent market capitalization for SIBN is USD 0.68B.
Based on targets from 4 analysts, the average taret price for SIBN is projected at USD 19.75 over the next 12 months.
This means that SIBN's stock price may go up by +45.22% over the next 12 months.
We can't find any ETFs which contains Si-Bone Inc's stock.
As per our most recent records Si-Bone Inc has 349 Employees.
Si-Bone Inc's registered address is 471 El Camino Real, Santa Clara, CA, United States, 95050.
You can get more information about it from Si-Bone Inc's website at https://si-bone.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Si-Bone Inc (SIBN) Stock
Based on ratings from 4 analysts Si-Bone Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on SIBN's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for SIBN is USD 19.75 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 15.
Unfortunately we do not have enough data on SIBN's stock to indicate if its overvalued.
The last closing price of SIBN's stock was USD 13.60.
The most recent market capitalization for SIBN is USD 0.68B.
Based on targets from 4 analysts, the average taret price for SIBN is projected at USD 19.75 over the next 12 months.
This means that SIBN's stock price may go up by +45.22% over the next 12 months.
We can't find any ETFs which contains Si-Bone Inc's stock.
As per our most recent records Si-Bone Inc has 349 Employees.
Si-Bone Inc's registered address is 471 El Camino Real, Santa Clara, CA, United States, 95050.
You can get more information about it from Si-Bone Inc's website at https://si-bone.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SIBN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
